Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer-Reference-Cited by-同舟云学术

Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer

Published:2024-06-11 Issue:5 Volume:31 Page:898-908
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Kitano Sae^ORCID,Tsunashima Ryo^ORCID,Kato Chikage,Watanabe Akira^ORCID,Sota Yoshiaki^ORCID,Matsumoto Saya,Morita Midori^ORCID,Sakaguchi Koichi,Naoi Yasuto^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12282-024-01602-5.pdf

Reference27 articles.

1. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16. https://doi.org/10.1016/S0140-6736(12)61963-1.

2. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31:5. https://doi.org/10.1200/jco.2013.31.18_suppl.5.

3. Schiavon G, Smith IE. Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res. 2014;16:206. https://doi.org/10.1186/bcr3636.

4. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71. https://doi.org/10.1093/jnci/dji250.

5. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–19. https://doi.org/10.1056/NEJMoa1604700.